ArticleBiomedical microdevices2026
Nanoyeast-based impedimetric biosensor with mutated single chain antigen-binding fragment anchoring for SARS-CoV-2 detection.
Article in Biomedical microdevices, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Impedimetric biosensors are useful for pathogen detection as they combine electrical impedance spectroscopy with the specificity of immunological reactions. These devices can be engineered to detect minute changes in electrical impedance caused by interactions between immobilized recognition elements and target antigens in a sample. They are advantageous in allowing for label-free and real-time detection, with the ability to operate without electroactive materials. Herein, we report an impedimetric biosensor containing nanoyeast expressing SARS-CoV-2 antibody fragments as the active layer. Using nanoyeast offers key advantages such as biocompatibility and stability. The single-chain antigen-binding fragment (scFab) against receptor binding domain of SARS-CoV-2 was mutated according to in silico predictions. It was expressed in Saccharomyces cerevisiae fused to the agglutinin 2 (Aga2), where the binding to Aga1 on the yeast cell wall displays the scFab on the surface of nanofragmented yeast (NY). Electrical impedance monitoring confirmed the successful immobilization of NY onto an adsorbed chitosan layer. This biosensor architecture detected SARS-CoV-2 spike protein with a limit of detection (LoD) of 5 × 10⁻¹⁸ g/mL. It distinguished viral concentrations ranging from 0.3 to 80 plaque-forming units per milliliter (PFU/mL) and demonstrated selectivity for SARS-CoV-2 over H1N1 influenza and Dengue virus. These findings suggest that this biosensing technology could be further adapted for other biomedical and clinical analyses, being promising to improve current pathogen detection methods.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.